Alere Inc. (ALR)

NYSE - NYSE Delayed Price. Currency in USD
44.53-0.37 (-0.82%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close44.90
Bid44.54 x 400
Ask44.57 x 400
Day's Range44.53 - 45.06
52wk Range31.47 - 54.13
1y Target EstN/A
Market Cap3.86B
P/E Ratio (ttm)-45.35
Avg Vol (3m)875,190
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    Alere Shareholders Approve Merger with Abbott

    WALTHAM, Mass., Oct. 21, 2016 /PRNewswire/ -- Alere Inc. (ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that its shareholders have voted to approve the previously announced merger with Abbott. "The overwhelming support we received from our shareholders today is recognition of the significant value that the combination of Alere and Abbott unlocks for our global customers, employees and shareholders," said Namal Nawana, President and CEO of Alere. Upon closing of the merger, Alere shareholders will receive $56 per common share in cash, and Alere will become a subsidiary of Abbott.

  • PR Newswire8 days ago

    People's Republic of China Clears Abbott Acquisition of Alere

    WALTHAM, Mass., Oct. 20, 2016 /PRNewswire/ -- Alere Inc. (ALR), a global leader in rapid diagnostics announced that it has received notification from the Ministry of Commerce of the People's Republic of China (PRC) that after completing its review of the proposed acquisition the PRC has decided not to prohibit the acquisition of Alere Inc. by Abbott Laboratories (ABT). As previously announced on February 1, 2016, Alere has entered into a definitive agreement under which Abbott will acquire Alere for $56 per common share in cash.

  • Zacks9 days ago

    New Strong Sell Stocks for October 19th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday